The Telangana Drugs Control Administration (DCA) has issued a public advisory cautioning against the unsupervised use of semaglutide formulations, amid rising demand for the drug for weight loss and Type-2 diabetes treatment following the expiry of the innovator product’s patent in March. The DCA has warned that the drug must be used under the strict supervision of a registered medical practitioner.
Semaglutide, a prescription-only medicine belonging to the class of Glucagon-Like Peptide-1 (GLP-1) receptor agonists, is increasingly being sought after for its role in regulating blood sugar levels and aiding weight reduction.
